A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis

NCT04274257 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Scleroderma, Systemic
Skin Sclerosis
Lung Fibrosis
Autoimmune Diseases
Collagen Diseases

Interventions

DRUG: Double-Blind Placebo
DRUG: Double-Blind Rituximab

Sponsor

Tokyo University

Collaborators

[object Object]
[object Object]